Goldman Sachs just slapped a buy rating on this ASX 200 tech stock

The broker thinks this market darling can keep rising.

| More on:
A man sits in casual clothes in front of a computer amid graphic images of data superimposed on the image, as though he is engaged in IT or hacking activities.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Pro Medicus Limited (ASX: PME) shares have been among the best performers on the ASX 200 index over the last 12 months.

During this time, the ASX 200 tech stock has risen an impressive 60%.

But if you were thinking the health imaging technology company's shares have now peaked, think again.

That's because analysts at Goldman Sachs believe that there could be more big returns ahead for investors.

What is Goldman saying about this ASX 200 tech stock?

According to a note from this morning, the broker has initiated coverage on Pro Medicus shares with a buy rating and a $134.00 price target.

Based on its current share price of $101.89, this implies a potential upside of almost 32% for investors over the next 12 months.

Why is Goldman bullish?

Goldman is feeling very positive about the ASX 200 tech stock's outlook due to its Visage 7 cloud-native picture archiving and communication systems (PACS) offering. It commented:

We believe Visage 7 is core to many healthcare institutions, providing efficiency gains in a market where demand for imaging continues to grow and radiologist shortages persist. Visage 7 has two advantages vs peers: speed and cloud capabilities, that have influenced the choice of PACS vendor, evident in the increasing cadence of PME's major contract wins.

The broker believes that the platform positions the company perfectly to almost double its market share in the United States in the coming years. It adds:

We see PME as well positioned into FY25E given a full year benefit of some large and high profile contracts (i.e. TCV >A$200m announced in 1H24), with long-term growth driven by: (1) growth in scan volumes given shift towards preventive medicine (+3% p.a.); (2) US market share gains to 13% in FY30E (c.7% today) as hospitals move to modern, cloud systems; (3) mid-high single digit price rises p.a. for new contracts, with renewals tracking at (or near) 100% given PME's competitive moat; and (4) growth opportunities in adjacent solutions.

Another reason the broker is positive is its artificial intelligence (AI) exposure.

We believe PME is well positioned to take share as the incumbent viewing platform across many large, and likely early adopters of new technology. PME is generating revenue from its Visage breast density AI algorithm (developed via a partnership with Yale) today, and we see the potential value for AI to be significant with adoption driven by improved accuracy and clinical outcomes. We forecast AI to comprise 9% of PME's revenue by FY30E (from <1% in FY25E), with upside if PME achieves faster AI attach penetration, higher price per scan, and a greater proportion of algorithms developed in-house where no royalties are paid to a partner.

All in all, this could be a great ASX 200 tech stock to buy if you're looking for exposure to this side of the market.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Technology Shares

Sports fans looking at smart phone representing surging pointsbet share price
Share Gainers

Guess which ASX All Ords share just rocketed 25% on an earnings upgrade

Investors are bidding up the ASX All Ords share following an improved FY 2024 earnings outlook.

Read more »

A man looking at his laptop and thinking.
Technology Shares

ASX 300 fallen star down 62% in a year hits new 52-week low: Time to buy?

Here's my take on Weebit Nano shares today.

Read more »

A man and woman watch their device screens, making investing decisions at home.
Technology Shares

Own Xero shares? Here's what to expect from next week's results

Strong earnings growth is expected from this market darling next week.

Read more »

A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
Technology Shares

Brokers name 2 rapidly growing ASX 200 tech stocks to buy

These tech stocks could be quality options for growth investors. Let's see why.

Read more »

a man weraing a suit sits nervously at his laptop computer biting into his clenched hand with nerves, and perhaps fear.
Technology Shares

What are 3 of the safest ASX 200 tech shares in Australia right now?

Here's how these tech companies stand out in a turbulent market.

Read more »

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Technology Shares

Buy this ASX 200 tech stock now before it's too late: Goldman Sachs

The broker sees potential for some big returns from this tech leader.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Technology Shares

Why is the Life360 share price sinking 9% today?

This high-flying tech stock has handed in its report card. How did it do?

Read more »

Smiling man working on his laptop.
Technology Shares

ASX tech stock up 54% on positive trading update

Integrated Research had some impressive news for its shareholders today.

Read more »